1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. アプリケーション別スニペット
3.2. 薬剤タイプ別スニペット
3.3. 販売チャネル別スニペット
3.4. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 神経変性疾患の増加
4.1.1.2.
4.1.2. 阻害要因
4.1.2.1. 薬剤に伴う副作用と忍容性の問題
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. 償還分析
5.6. 特許分析
5.7. SWOT分析
5.8. DMI意見
6. アプリケーション別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析（%）, アプリケーション別
6.1.2. 市場魅力度指数（用途別
6.2. アルツハイマー病*市場
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. パーキンソン病
6.4. レビー小体型認知症
6.5. 重症筋無力症
7. 薬剤タイプ別
7.1. はじめに
7.1.1. 薬物タイプ別市場規模分析および前年比成長率分析（%） 7.1.2.
7.1.2. 市場魅力度指数（薬物タイプ別
7.2. ドネペジル（アリセプト）*市場
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. ガランタミン（ラザダイン）
7.4. ALPHA-1062（ズンベイル）
7.5. タクリン
7.6. フィソスチグミン
7.7. メマンチン
8. 流通チャネル別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
8.1.2. 市場魅力度指数（流通チャネル別
8.2. 病院薬局
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 小売薬局
8.4. オンライン薬局
8.5. その他
9. 地域別
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析(%)、用途別
9.2.4. 市場規模分析およびYoY成長率分析（%）, 薬剤タイプ別
9.2.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.2.6. 市場規模分析および前年比成長率分析（%）, 国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. 市場規模分析および前年比成長率分析(%)、用途別
9.3.4. 市場規模分析およびYoY成長率分析（%）, 薬剤タイプ別
9.3.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.3.6. 市場規模分析および前年比成長率分析（%）, 国別
9.3.6.1. ドイツ
9.3.6.2. イギリス
9.3.6.3. フランス
9.3.6.4. イタリア
9.3.6.5. スペイン
9.3.6.6. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. 市場規模分析および前年比成長率分析(%)、用途別
9.4.4. 市場規模分析およびYoY成長率分析（%）, 薬剤タイプ別
9.4.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.4.6. 市場規模分析および前年比成長率分析（%）, 国別
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. その他の南米諸国
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. 市場規模分析および前年比成長率分析(%)、用途別
9.5.4. 市場規模分析およびYoY成長率分析（%）, 薬剤タイプ別
9.5.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.5.6. 市場規模分析および前年比成長率分析（%）, 国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. 市場規模分析および前年比成長率分析(%)、用途別
9.6.4. 市場規模分析およびYoY成長率分析（%）, 薬剤タイプ別
9.6.5. 市場規模分析および前年比成長率分析 (%)、流通チャネル別
10. 競合情勢
10.1. 競争シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. Eisai Co., Ltd.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Pfizer Inc.
11.3. Alkem
11.4. Zydus Group
11.5. Teva Pharmaceutical Industries Ltd
11.6. Indena S.p.A.
11.7. Alpha Cognition
11.8. Dr. Reddy’s Laboratories Ltd.
11.9. Aurobindo Pharma
11.10. Merz Pharma
リストは網羅的ではありません
12. 付録
12.1. 会社概要とサービス
12.2. お問い合わせ
The global acetylcholinesterase inhibitors market reached US$ 5.03 billion in 2023 and is expected to reach US$ 9.03 billion by 2031, growing at a CAGR of 7.8% during the forecast period 2024-2031.
Acetylcholinesterase inhibitors (AChEIs) are a specific kind of drug that is essential in the treatment of a variety of neurological illnesses, including Alzheimer's disease and other forms of dementia. These medications work by blocking the enzyme acetylcholinesterase, which breaks down acetylcholine, a critical neurotransmitter involved in memory, learning, and muscular activity. AChEIs block acetylcholine breakdown, increasing its levels and prolonging its effect at synaptic junctions, hence improving cholinergic communication in the brain.
The increasing prevalence of alzheimer's disease is the driving factor that drives the market over the forecast period. For instance, according to Alzheimer's Disease International, Every three seconds, someone somewhere in the globe develops dementia. In 2020, more than 55 million individuals globally will be living with dementia. This figure will nearly double every twenty years, reaching 78 million in 2030 and 139 million in 2050. Much of the increase will occur in underdeveloped countries. Already, 60% of people with dementia live in low- and middle-income nations, by 2050, the proportion will grow to 71%. China, India, and their South Asian and Western Pacific neighbors are experiencing the fastest aging population rise.
Market Dynamics: Drivers & Restraints
Increasing prevalence of neurodegenerative diseases
The rising burden and increasing prevalence of neurodegenerative diseases is expected to be a significant factor in the growth of the global acetylcholinesterase inhibitors market. The increased burden and prevalence of neurodegenerative disorders, including Alzheimer's disease and other types of dementia, are key drivers of the global acetylcholinesterase inhibitors market. As the population ages and the prevalence of these debilitating disorders increases, there will be a greater demand for effective therapeutic choices.
For instance, according to the World Health Organization, Dementia affects around 55 million individuals globally, with more than 60% living in low- and middle-income countries. Every year, there are roughly 10 million new cases. Dementia is caused by a range of brain-related disorders and accidents. Alzheimer's disease is the most common type of dementia and may account for 60-70% of cases. Dementia is now the seventh largest cause of death and one of the primary causes of impairment and dependency among the elderly worldwide. Women are disproportionately impacted by dementia, both directly and indirectly. Women had greater disability-adjusted life years and mortality rates from dementia, but they also gave 70% of care hours for people with dementia.
The increased burden and prevalence of neurodegenerative disorders are major factors supporting the growth of the acetylcholinesterase inhibitors market. As more people are diagnosed with diseases such as Alzheimer's disease, the demand for effective treatments will increase, leading to innovation and growth in this vital section of the pharmaceutical business. The continuous commitment to research and development will be critical in addressing both present obstacles and future prospects for effective neurodegenerative disease management.
Side Effects and Tolerability Issues Associated with Drugs
Factors such as side effects and tolerability issues associated with drugs are expected to hamper the global acetylcholinesterase inhibitors market. For instance, according to the National Institute of Health, acetylcholinesterase inhibitors increase the overall amount of acetylcholine available. Thus, symptoms of overstimulation of the parasympathetic nervous system, such as increased hypermotility, hypersecretion, bradycardia, miosis, diarrhea, and hypotension, may be present. One of the primary concerns with AChEIs is the incidence of gastrointestinal adverse effects. Common symptoms include nausea, vomiting, diarrhea, and anorexia.
Segment Analysis
The global acetylcholinesterase inhibitors market is segmented based on application, drug type, distribution channel, and region.
Alzheimer’s disease segment is expected to dominate the global acetylcholinesterase inhibitors market share
Alzheimer’s disease segment is expected to dominate the global acetylcholinesterase inhibitors market share. The Alzheimer's disease market is anticipated to dominate the global acetylcholinesterase inhibitors market, owing to the disease's increasing prevalence and the growing acceptance of acetylcholinesterase inhibitors (AChEIs) as a conventional treatment. Alzheimer's disease, the most common type of dementia, affects millions of people globally, and its rising prevalence is a major factor driving the growth of this market sector. For instance, according to the Alzheimer’s Association, Alzheimer's dementia affects around 6.7 million Americans aged 65 and older. If no medical breakthroughs are developed to prevent, halt, or cure Alzheimer's disease, this figure might rise to 13.8 million by 2060. In 2019, official death certificates documented 121,499 deaths from Alzheimer's disease, making it the sixth-highest cause of death in the United States.
The acetylcholinesterase inhibitors play an important role in the treatment of alzheimer’s disease. Acetylcholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, are among the few approved pharmaceutical treatments for Alzheimer's disease symptoms. These drugs act by preventing the breakdown of acetylcholine, a neurotransmitter necessary for memory and cognitive function. AChEIs, which increase acetylcholine levels in the brain, can assist improve cognitive performance and halt symptom development in people with mild to moderate Alzheimer's disease. Numerous clinical trials have supported the efficacy of these medications, confirming their status as an essential component in Alzheimer's treatment.
Geographical Analysis
North America is expected to hold a significant position in the global acetylcholinesterase inhibitors market share
North America is expected to hold a significant portion of the global acetylcholinesterase inhibitors market. North America is expected to dominate the global acetylcholinesterase inhibitors market, owing to demographic trends, high prevalence rates of neurological disorders, and developments in healthcare infrastructure. As the region experiences an increase in the number of people diagnosed with Alzheimer's disease and other forms of dementia, there will be a greater demand for effective treatment alternatives like acetylcholinesterase inhibitors.
For instance, according to the Alzheimer’s Association, Alzheimer's affects around 7 million Americans. By 2050, this figure is expected to increase to approximately 13 million. Alzheimer's disease was the fifth greatest cause of mortality for those aged 65 and up. Health and long-term care costs for people with dementia are expected to exceed $360 billion in 2024 and nearly $1 trillion by 2050. At the age of 45, women have a one-in-five lifetime risk of developing Alzheimer's, while males have one in ten. Over 11 million Americans offer unpaid care to persons suffering from Alzheimer's disease or other forms of dementia.
North America has an established healthcare system, making improved therapeutic choices available to patients suffering from neurodegenerative illnesses. The region is home to various research institutions and pharmaceutical businesses that develop and market AChEIs, ensuring that patients have access to the most recent therapy options. The availability of well-established hospital systems, outpatient facilities, and specialized dementia care centers improves patient access to critical drugs and supportive services.
Asia Pacific is growing at the fastest pace in the global acetylcholinesterase inhibitors market
The Asia Pacific area is emerging as the fastest-growing market for acetylcholinesterase inhibitors (AChEIs), owing to a combination of demographic, healthcare, and economic drivers. As the frequency of neurodegenerative disorders, particularly Alzheimer's disease and other kinds of dementia, rises in this highly populated region, there will be a huge increase in demand for effective therapy choices. For instance, according to the Alzheimer’s Association, The estimated dementia prevalence in individuals aged 60 and up in India is 7.4%. There are an estimated 8.8 million Indians over the age of 60 who suffer from dementia. Dementia affects more women than men, and it is more prevalent in rural regions than in cities.
Competitive Landscape
The major global players in the global acetylcholinesterase inhibitors market include Eisai Co., Ltd., Pfizer Inc., Alkem, Zydus Group, Teva Pharmaceutical Industries Ltd, Indena S.p.A., Alpha Cognition, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, Merz Pharma among others.
Emerging Players
Biogen, Anavex Life Sciences Corp. among others
Key Developments
• In July 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease. ALPHA-1062 is absorbed in the small intestine as an insert medication. The addition of a benzyl ester to galantamine inhibits its binding to AChE in the gastrointestinal nervous system. This minimizes overstimulation of local neurons, and gastrointestinal adverse events, and enhances absorption.
Why Purchase the Report?
• To visualize the global acetylcholinesterase inhibitors market segmentation based on application, drug type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global acetylcholinesterase inhibitors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global acetylcholinesterase inhibitors market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Application
3.2. Snippet by Drug Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Neurodegenerative Diseases
4.1.1.2.
4.1.2. Restraints
4.1.2.1. Side Effects and Tolerability Issues Associated with Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Application
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Alzheimer’s Disease*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Parkinson Disease
6.4. Lewy Body Dementia
6.5. Myasthenia Gravis
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Donepezil (Aricept)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Galantamine (Razadyne)
7.4. ALPHA-1062 (Zunveyl)
7.5. Tacrine
7.6. Physostigmine
7.7. Memantine
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Eisai Co., Ltd.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Pfizer Inc.
11.3. Alkem
11.4. Zydus Group
11.5. Teva Pharmaceutical Industries Ltd
11.6. Indena S.p.A.
11.7. Alpha Cognition
11.8. Dr. Reddy’s Laboratories Ltd.
11.9. Aurobindo Pharma
11.10. Merz Pharma
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us
❖ 世界のアセチルコリンエステラーゼ阻害剤市場に関するよくある質問(FAQ) ❖
・アセチルコリンエステラーゼ阻害剤の世界市場規模は？
→DataM Intelligence社は2023年のアセチルコリンエステラーゼ阻害剤の世界市場規模を50億3,000万米ドルと推定しています。
・アセチルコリンエステラーゼ阻害剤の世界市場予測は？
→DataM Intelligence社は2031年のアセチルコリンエステラーゼ阻害剤の世界市場規模を90億3,000万米ドルと予測しています。
・アセチルコリンエステラーゼ阻害剤市場の成長率は？
→DataM Intelligence社はアセチルコリンエステラーゼ阻害剤の世界市場が2024年～2031年に年平均7.8%成長すると予測しています。
・世界のアセチルコリンエステラーゼ阻害剤市場における主要企業は？
→DataM Intelligence社は「Eisai Co., Ltd., Pfizer Inc., Alkem, Zydus Group, Teva Pharmaceutical Industries Ltd, Indena S.p.A., Alpha Cognition, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, Merz Pharmaなど ...」をグローバルアセチルコリンエステラーゼ阻害剤市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
